News
FDA okays Daiichi Sankyo’s Vanflyta for first-line AML
Daiichi Sankyo’s Vanflyta has become the first drug in the US to be approved for newly-diagnosed acute myeloid leukaemia (AML) with FLT3-ITD mutations, nearly four years a
